China NMPA Drug Inspection - Place of origin: Hebei - Kochia scoparia

On March 25, 2020, the Jiangxi Provincial Drug Administration (NMPA) released its second 2020 drug inspection announcement, detailing quality failures across 33 batches of 30 drug varieties. The inspections, conducted under the framework of the Chinese Drug Administration Law and the 2015 Chinese Pharmacopoeia, identified significant quality control issues at several firms, including Xiangyu Pharmaceutical Co., Ltd., Shanxi Fenhe Pharmaceutical, and Guangdong Bozhou Pharmaceutical. The primary violations involved technical failures such as 'content determination' (incorrect amounts of active ingredients), 'weight variation' (inconsistency in tablet size), and excessive 'related substances' (impurities). Other notable issues included failed dissolution tests, excessive moisture content, and deviations in physical appearance and characteristics. In response, the Jiangxi Provincial Drug Administration has mandated immediate regulatory actions. Authorities have instructed relevant departments to seal and seize the affected products, suspend all sales, and initiate recalls of non-compliant batches. Furthermore, the administration has launched formal investigations into the manufacturers and distributors involved to determine legal penalties and ensure future adherence to national safety standards.